This Guidelines summary covers the provision of care for patients requiring dialysis in the context of the COVID-19 outbreak
This COVID-19 rapid guideline aims to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.
For information on assessing risk factors in adults having iodine-based contrast media or surgery, ongoing assessment of the condition of people in hospital, and preventing acute kidney injury in adults having iodine-based contrast media, see the full guideline.
This summary provides a treatment algorithm for the appropriate prescribing of antimicrobials for acute pyelonephritis.
Non-vitamin K oral anticoagulant options for patients with non-valvular atrial fibrillation and renal impairment
This NOAC dosing guide has been commissioned by Bayer, who also provided funding for its development. Bayer reviewed and approved the scope and pre-meeting documents, suggested the Chair and experts for the group, and put the dosing guide through full medical approval to ensure its compliance with appropriate regulations.